NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
April 01, 2024 at 06:12 pm IST
Share
NEXGEL, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 4.09 million compared to USD 2.05 million a year ago. Net loss was USD 3.16 million compared to USD 4.75 million a year ago.
Basic loss per share from continuing operations was USD 0.56 compared to USD 0.85 a year ago.
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Companyâs converting and packaging business, which is based in Granbury, Texas. All of its gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty.
NEXGEL, INC. 